Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial

BACKGROUND: The Evaluate Patient OutComes (EPOC) study assessed physician- and patient-reported outcomes in individuals with relapsing multiple sclerosis who switched directly from injectable disease-modifying therapy (iDMT; glatiramer acetate, intramuscular or subcutaneous interferon beta-1a, or in...

Descripción completa

Detalles Bibliográficos
Autores principales: Calkwood, Jonathan, Cree, Bruce, Crayton, Heidi, Kantor, Daniel, Steingo, Brian, Barbato, Luigi, Hashmonay, Ron, Agashivala, Neetu, McCague, Kevin, Tenenbaum, Nadia, Edwards, Keith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253981/
https://www.ncbi.nlm.nih.gov/pubmed/25424122
http://dx.doi.org/10.1186/s12883-014-0220-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253981/
https://www.ncbi.nlm.nih.gov/pubmed/25424122
http://dx.doi.org/10.1186/s12883-014-0220-1

Ejemplares similares